We are live on ! Find out more
HBIO icon

Harvard Bioscience

69 hedge funds and large institutions have $60.6M invested in Harvard Bioscience in 2016 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 28 increasing their positions, 22 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

27% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 22

7% less capital invested

Capital invested by funds: $65.1M → $60.6M (-$4.49M)

15% less funds holding

Funds holding: 8169 (-12)

80% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 15

Holders
69
Holders Change
-12
Holders Change %
-14.81%
% of All Funds
1.84%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
3
Increased
28
Reduced
22
Closed
15
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
EIM
26
Essex Investment Management
Massachusetts
$431K -$10.3K -370 -2%
EGA
27
Eagle Global Advisors
Texas
$425K -$41.9K -1,508 -9%
Geode Capital Management
28
Geode Capital Management
Massachusetts
$395K +$39.1K +1,408 +11%
California Public Employees Retirement System
29
California Public Employees Retirement System
California
$379K
PM
30
Penbrook Management
New York
$364K
SIM
31
Spark Investment Management
New York
$281K +$190K +6,850 +196%
Bank of America
32
Bank of America
North Carolina
$272K -$37K -1,334 -12%
BFA
33
BlackRock Fund Advisors
California
$265K +$49K +1,765 +22%
D.E. Shaw & Co
34
D.E. Shaw & Co
New York
$207K +$18.1K +651 +9%
Northern Trust
35
Northern Trust
Illinois
$206K +$1.36K +49 +0.7%
First Manhattan
36
First Manhattan
New York
$174K +$55.5K +2,000 +45%
Invesco
37
Invesco
Georgia
$157K +$31K +1,118 +24%
AG
38
Algert Global
California
$132K +$135K +4,867 New
Millennium Management
39
Millennium Management
New York
$125K -$433K -15,581 -77%
PAM
40
Panagora Asset Management
Massachusetts
$121K +$44.9K +1,617 +57%
Bank of New York Mellon
41
Bank of New York Mellon
New York
$106K -$31.1K -1,119 -22%
TC
42
TFS Capital
Pennsylvania
$88K -$310K -11,166 -77%
T. Rowe Price Associates
43
T. Rowe Price Associates
Maryland
$77K
Two Sigma Advisers
44
Two Sigma Advisers
New York
$74K -$9.16K -330 -11%
BG
45
BlackRock Group
United Kingdom
$72K
EA
46
Emerald Acquisition
Washington
$71K
Asset Management One
47
Asset Management One
Japan
$70K
Morgan Stanley
48
Morgan Stanley
New York
$57K -$28.5K -1,028 -33%
Charles Schwab
49
Charles Schwab
California
$53K
JP Morgan Chase
50
JP Morgan Chase
New York
$52K +$47.6K +1,714 +832%

HBIO Hedge Fund Activity: Q3 2016 in Review

69 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Harvard Bioscience (HBIO) for Q3 2016, worth a combined $60.6M — down 6.9% from $65.1M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of HBIO and 3 opened new positions — a net loss of 12 holders — while 22 trimmed existing stakes and 28 added.

The largest buyer was Kennedy Capital Management, opening a new position worth an estimated $1.36M. The largest seller was Polar Asset Management Partners, cutting an estimated $1.64M.

  • 69 institutional investors held Harvard Bioscience (HBIO) as of Q3 2016, down from 81 in Q2 2016.
  • Funds reported $60.6M of Harvard Bioscience stock for Q3 2016, down 6.9% quarter-over-quarter.
  • 3 funds opened new Harvard Bioscience positions in Q3 2016 and 15 closed out, a net change of -12 holders.
  • The largest Harvard Bioscience buyer in Q3 2016 was Kennedy Capital Management, an estimated $1.36M added.
  • The largest Harvard Bioscience seller in Q3 2016 was Polar Asset Management Partners, an estimated $1.64M sold.

Based on aggregated 13F filings for Q3 2016.